Greetings, and welcome to the Simulations Plus Fourth Quarter Fiscal 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Brian Siegel from Hayden IR. Thank you, Mr. Siegel. You may begin your presentation.

Good afternoon, everyone. Welcome to our fourth quarter fiscal 2021 financial results conference call. Hosting the call today are Simulations Plus' CEO, Shawn O'Connor, and CFO, Will Frederick. An opportunity to ask questions will follow today's presentation. Before beginning, I would like to remind everyone that except for historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. Words like believe, expect, anticipate, mean that these are our best estimates at the time, but that there can be no assurances that expected or disappeared results or events will actually take place. So our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisition on terms favorable to the company and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission. With that said, I would like to turn over the call to Shawn O'Connor. Shawn?

Thank you, Brian. We had an encouraging end to the fiscal year as we saw continued momentum in our software business and the decline in our services business was less than we saw in the prior quarter. For fiscal 2021, our total revenue growth came in at 12%, exceeding our guidance of 5% to 10%. Software revenue growth for fiscal 2021 was 28%, exceeding our guidance of 20% to 25%. And the service revenue decline was 6%, slightly better than our guidance of 7% to 12%. Our software business had a good quarter, reflecting the strength of both GastroPlus and ADMET Predictor, each growing by at least 20%, partially offset by the expected decline in MonolixSuite due to early renewals that occurred in prior quarters. Software revenue growth in fiscal 2021 increased to 28% compared to last fiscal year's growth rate of 17% and 11% in fiscal 2019. GastroPlus revenues grew 20% in the fourth quarter and we attribute this strong performance to our industry-leading technology and focused upselling efforts, which produced 14 new commercial contracts during the quarter. During the fourth quarter, GastroPlus also saw 17 peer-reviewed journal articles, reflecting the strength and recognition of our industry-leading PBPK platform. ADMET Predictor revenue growth in the fourth quarter was 26% as it continued to benefit from the Q3 product release that added valuable new features and functionality. Additionally, I want to emphasize that both GastroPlus and ADMET Predictor continued to expand their strong leadership position in the market during the year. For example, we saw 20 multi-year GastroPlus licenses signed, three new $100,000-plus customers and 14 upsells during the year, and our new DDI module has been very well received, all of which are a strong validation of our leadership position. As anticipated, MonolixSuite revenue declined in the fourth quarter due to early renewals in prior quarters. For the full year, revenue growth was 20% as we continue to see both new commercial clients adopting as well as displacing alternative products and taking market share from our primary competitor. Turning to our services business, as a reminder, our service revenue is nonrecurring. Accordingly, this business can exhibit volatility, both quarterly and annually. PK/PD projects are typically in the $100,000 to $200,000 range and QSP/QST projects can be significantly larger. Sometimes these projects are accelerated, delayed or even canceled by our customers based on their internal priorities or timelines and are not under our control. While it was a challenging second half of the fiscal year due to the uncharacteristic events of the third quarter with higher than normal customer project delays and cancellations, we saw signs of optimism during the fourth quarter as revenue decreased less than expected, our backlog grew sequentially and our pipeline continued to build. During Q4, we saw the number of customer project delays and cancellations return to more normal levels. We also had a good bookings quarter, highlighted by closing five new clients, which contributed to a 10% increase in backlog for the quarter and a 49% increase for the full year, which was about 110% of our internal target. During the quarter, we also provided critical support for a multi-regional regulatory approval and supported an FDA submission for a new COVID-19 therapy. For the year, we took action and made several operational improvements that drove margin enhancements leading to increased average contract value project yield and consultant utilization rates. For the QSP/QST business, revenue was down in Q4 as expected. Despite this decline, we saw positive signs that point to an inflection point in this business. We had one new and one renewal of DILIsym consortium members during the quarter and overall pipeline activity accelerated, reflecting strong momentum as we enter fiscal 2022. We are also seeing toxicology project opportunities picking up and have multiple QSP projects in late-stage proposal status. I am also encouraged that we have already achieved our bookings target for Q1 of the new fiscal year. And finally, our PBPK business saw a 63% increase in backlog for the year and finished strong with two significant FDA-funded projects announced during Q4. Looking to fiscal 2022, modeling and simulation adoption continues to be strong in the pharma and biotech marketplace. Internal modeling and simulation resources continue to grow and they are seeking our software platforms to achieve their objectives. Outsourcing also remains a robust part of our clients' efforts to meet their needs, and we are here to support them with our service business. Our software business carries strong momentum into the new year as we continue increasing our revenue growth rate as a result of enhancements to our technology, ongoing product portfolio expansion both internally and through acquisitions and investments in our sales and marketing efforts. In fiscal 2021, our service business experienced a downside of what can be a volatile business, but we saw no fundamental changes in the market that would prevent this business from returning as a positive contributor to revenue growth in the future. Despite this decline in fiscal 2021, we enter the new year with increased pipeline activity, a rebuilt backlog that should drive sequential revenue growth on a quarterly basis in fiscal 2022. With these positive tailwinds, the financial outlook we are providing today anticipates a recovery of our services business and growth accelerating sequentially as the fiscal year progresses. We expect to return to double-digit growth and total revenue in the range of $51 million to $53 million, reflecting 10% to 15% year-over-year growth. We expect software to be in the range of 55% to 60% of total revenue and services to be in the range of 40% to 45% of total revenue. And finally, we will continue our successful merger and acquisition strategy to expand our software portfolio and service offerings and grow our overall market opportunity to broaden our capabilities and further support our clients. Of course, any acquisition would be incremental to this outlook, and with future acquisitions, we believe we can continue to grow at a pace that supports our CAGR target above 20% that we have achieved since the Cognigen acquisition in fiscal 2015. Let me now turn the call over to our CFO, Will Frederick, to discuss the financial results.

Thank you, Shawn. Our total revenue growth rate for the quarter was 3% due to the challenges in our services business and the early MonolixSuite renewals that occurred in prior quarters. Software revenue growth for the quarter was 14%, and services revenue declined 7% for the quarter. We continue to see improvement in our software and services revenue mix, with software now at 55% of total revenue for the quarter. Our total revenue growth rate for the fiscal year was 12%. Software revenue growth for the fiscal year was 28%. And services revenue declined 6% for the fiscal year. For the fiscal year, software is now at 60% of total revenue. For the quarter, software gross margin increased from 83% last fiscal year to 85% this fiscal year due to the increased revenue in that business. The services gross margin for the quarter decreased from 61% to 55% due to the revenue decline in that business. The revenue mix trends positively affected our total gross margin for the quarter, which remained at 72%, comparable to last fiscal year. For the fiscal year, software gross margin increased from 87% last year to 88% this year, and the services gross margin for the fiscal year remained unchanged at 61%. The revenue mix shift had a greater impact on total gross margin for the fiscal year, and our total gross margin increased from 74% to 77%. For the quarter, GastroPlus represented 57% of our software revenue, ADMET Predictor was 22%, MonolixSuite was 15% and other software was 6%. For the year, GastroPlus represented 59% of our software revenue, ADMET Predictor was 18%, MonolixSuite was 16% and other software was 7%. We continue to enjoy solid revenue growth and diversification across our entire portfolio as evidenced by the software mix change since last year when GastroPlus was 66% of our software revenue and MonolixSuite was only 7%. We continue to see improvement in our average revenue per customer again this quarter, with an increase from $62,000 to $65,000 for commercial companies and from $42,000 to $55,000, including nonprofits and academic customers. Our renewal rate for the quarter based on fees was 90%, up from 88% last fiscal year, and would have been higher except with five customer renewals that slipped into the next quarter. Our renewal rate this quarter based on customers was 77%, down from 93% as expected with our recently announced University+ program that offers free access to our software for students and educators as part of our ongoing support of academic research training and collaborations. We believe this program will increase modeling and simulation education and help prepare the next generation of scientists and contribute to the rapid development of safer, lower-cost treatments for patients worldwide. With this program, we saw a decline in paid nonprofit and academic renewals and will exclude them from our reporting beginning next fiscal year. For the fiscal year, we also saw improvement in our average revenue per customer with an increase from $111,000 to $121,000 for commercial companies and from $69,000 to $85,000, including nonprofits and academic customers. Our fiscal year average revenues per customer are higher than those of the quarter due to larger deals that occurred during the fiscal year. Our renewal rate for the fiscal year based on fees was 92%, down slightly from 93% last fiscal year due to the customer renewals slippage for the five customers I just mentioned. Our renewal rate this fiscal year based on customers was 83%, down from 89%, primarily due to nonprofit non-renewals as they transitioned to the University+ program. Let me shift now to our services business. For the quarter, our services revenue breakdown was 53% from PK/PD services, 25% from QSP, QST services, 16% from PBPK services and 6% from other services. For the full year, the breakdown was 49% from PK/PD services, 28% from QSP, QST services, 14% from PBPK services and 9% from other services. With regard to a couple of key service metrics, total service projects completed during the year increased 36% compared to the prior fiscal year, which increased 24% compared to fiscal 2019. We started breaking out other projects this fiscal year that were previously reported in PK/PD, QSP, QST or PBPK to provide additional visibility to this increasing activity and reflect the continued expansion of our services offerings. We ended the fiscal year with $13 million in backlog, up $2.5 million from prior fiscal year, reflecting a 24% increase and a nice recovery from the decline we saw at the end of fiscal 2020 compared to fiscal 2019. Now turning to our consolidated income statement. SG&A expense for the quarter was $5.6 million or 57% of revenue, compared to $3.7 million or 39% of revenue in the same period last fiscal year. Approximately $700,000 of this increase was a catch-up this quarter as a result of switching from a semi-monthly payroll to a biweekly payroll during the fiscal year. As part of our integration efforts and One Company focus, we consolidated our payroll for all US employees and moved to a biweekly payroll. The true-up with seven payroll periods in Q4 is reflected in the quarter and has no impact on our fiscal year expense. We have also seen cost increases since last fiscal year in insurance, external professional fees, recruiting and stock compensation expense. Lastly, we had salary increases during the fiscal year to remain competitive with increasing market salaries, and we increased our headcount by nine employees during the fiscal year, from 137 to 146. Total R&D costs for the quarter were $2 million or 20% of revenue, compared to $1.6 million or 17% of revenue in the same period last fiscal year. R&D expenses for the quarter were $1.3 million or 13% of revenue, compared to $0.9 million or 9% of revenue in the same period last fiscal year. Capitalized R&D for the quarter was $0.7 million or 7% of revenue, compared to $0.6 million or 6% of revenue in the same period last fiscal year. Income from operations was $0.2 million compared to $2.2 million in the same period last fiscal year. This decrease was primarily driven by the higher SG&A costs I just described plus increased spending on R&D to support our product development efforts. The income tax benefit was $0.1 million for an effective tax rate of negative 73%, compared to an income tax benefit of $0.2 million and effective tax rate of negative 7% in the same period last year. We continue to see a lower effective tax rate, primarily driven by the tax benefit associated with disqualifying dispositions that we have seen throughout the fiscal year. Net income was $0.3 million compared to $2.2 million for the same period last fiscal year. And diluted earnings per share was $0.01 compared to $0.11 for the same period last fiscal year. EBITDA was $1.1 million compared to $2.9 million for the same period last fiscal year. For the fiscal year, SG&A expenses were $20.6 million or 44% of revenue compared to $16.4 million or 39% of revenue last year. The increase in SG&A expenses was primarily the result of higher payroll-related expenses due to increased compensation to remain competitive with increasing market salaries and the increased headcount I just mentioned. We have also seen cost increases since last fiscal year in contract labor, insurance, professional fees and stock compensation expenses driven by our stock price during the fiscal year. Total R&D costs were $6.9 million or 15% of revenue, compared to $5.3 million or 13% of revenue in the same period last fiscal year. R&D expenses were $4 million or 9% of revenue, compared to $3 million or 7% of revenue in the same period last fiscal year. Capitalized R&D for the year was $2.9 million or 6% of revenue, compared to $2.3 million, also 6% of revenue in the same period last fiscal year. Income from operations was $11.3 million, compared to $11.6 million last fiscal year. Income tax expense was $1.3 million for an effective tax rate of 12%, compared to an income tax expense of $2.1 million and effective tax rate of 18% for last year. As previously mentioned, we saw a lower effective tax rate throughout this fiscal year, primarily driven by the tax benefit associated with disqualifying dispositions. Net income increased 5% to $9.8 million, compared to $9.3 million for last fiscal year. And diluted earnings per share were $0.47, compared to $0.50 last fiscal year. Adding back the 2.1 million shares of common stock issued in our follow-on offering last August would result in diluted earnings per share increasing to $0.52 this fiscal year compared to last year. EBITDA also increased to $14.5 million, compared to $14.3 million for the same period last fiscal year. We continue to have a strong balance sheet. At the end of the fiscal year, our cash and short-term investments balance was $123.6 million, compared to $116 million at the end of last fiscal year. Our strong balance sheet reduces the need to secure additional capital as we are continually evaluating strategic acquisition opportunities that we believe can further position us for success and support our long-term revenue targets. We also continue to have no debt on the balance sheet. I will now turn the call back to you, Shawn.

Thank you, Will. In conclusion, strategically, we continue to reinforce our leadership in our portion of the biosimulation market for pharmaceuticals as the industry's adoption of model-informed drug development tools and techniques continues to expand at a rate four to five times that of overall R&D. We remain well integrated with both academia and regulatory agencies, giving us scientific capability as we look to the future. As a result, our software business is doing very well with accelerated growth rates and expanded capabilities. And our service business is steadily normalizing as evidenced by our improving backlog and strong bookings. This performance gives us confidence that we have a clear line of sight to delivering consistent longer-term growth in line with our growth expectations. With that, I will be happy to take your questions. Operator?

At this time, we will be conducting a question-and-answer session. Thank you, sir. Our first question comes from Matt Hewitt with Craig-Hallum Capital Group. You may proceed with your question.

Good afternoon. Thank you for taking the questions, and it's nice to see the bounce back in the services side of the business. Maybe to dig in a little bit there, last quarter, as you called out on the last call, was abnormal in the number of cancellations, deferrals, and whatnot. It seems to have bounced back very quickly. What are you hearing from your customers? Have any of those contracts that were maybe deferred, have those closed? Any incremental color on the services side would be helpful.

Sure, Matt. Yes, it headed back to normalization. And normalization doesn't mean that there are no cancellations or delays or holds; it peaked in the third quarter, but down to a level which, as I said before, is difficult. Two or three of these occurrences during a quarter is something that we can manage around more adeptly. So good outcome in that regard. Is there any market indicator as to why the frequency stepped back down? Hard to pinpoint. In the toxicology area and the QSP area, we are seeing some indication based upon request for proposals and a healthy increase in our pipeline. The FDA response is back to companies has picked up, and that's a good sign. So certainly can point to that. I would say that it is still a market in terms of our PK/PD services where projects come under greater scrutiny, I think, than in the past and holds or delays and ultimately cancellations. As I think I have said before, our good sign that the fail-fast move to the next drug opportunity when this one indicates a less than likely success profile. I think that's the phenomenon that is a good one, and we are going to have to manage our service business around it on a go-forward basis. But other than that, no flare guns from the marketplace.

That's great. Shifting to the software side, a good quarter, better than our estimates anyway. Yet it sounds like you had five renewals that slipped. Have any of those closed already here in Q4? And is there anything to kind of pick out with those five? Or is it just a timing situation?

All five closed in the week after the end of the year.

That's great. Okay. And then maybe one last one for me and then I will hop back into the queue. You mentioned that you are seeing continued market share gains. And I am just curious if you have seen anything from a competitive response? Or is this something that we shouldn't expect as we get into 2022 and into 2023? Are you going to continue to take share? Thank you.

Yes. Our comments there are specifically with regard to Monolix, and their growth is certainly well ahead of the growth for NMLE applications out there as a whole overall market growth. So clearly, we are taking some market share of the existing players there. Have we seen a response in that regard? Nothing of great significance. The market for Monolix is responding very favorably to its ease of use, the workflow approach, and quite frankly, our clients are attracted to the same benefit that we see internally where we are completing PK to PD projects more efficiently and utilizing less time to get to the end of the job when we use Monolix. So very good progress on the Monolix side, and it continues its momentum into next year.

Our next question comes from the line of Francois Brisebois with Oppenheimer. You may proceed with your question.

Hi. Thanks for the questions. Just quickly here, I was wondering what makes you so confident; $51 million to $53 million is pretty tight? What gives you confidence to give guidance due to the fact that it seems like this pandemic is lingering quite a bit? So any factors there?

Well, two sides of our business. On the software side, with its high recurring revenue, renewal rates gives us the benefit of being pretty confident in terms of the direction of that business. And it's really picked up in the back half of this year. Really, over the last couple or three years, we have seen the organic growth rate of our software business step up and continue to deliver higher growth rates. And so our software business is performing very well. The COVID impact there, even when we look back at the brunt of the COVID impact a couple of years ago, our software business wasn't unaffected but was minimally affected. So high degree of confidence on the software side; still cautious on the service side. That is where COVID can have its biggest impact, with the disruption in terms of clinical trial timing, programs being altered and changed and reallocated to other programs in response to things like COVID. And there, we keep a little bit higher discount factor in our heads as we prepare guidance. But the combination of those two gives us high confidence in an environment that software is performing well. And on the service side, our underlying pipeline and building a backlog, new contracts being closed is moving quite nicely as we exited the year and began the year here in fiscal year 2022.

Okay. Great. And this has been touched on in the past, but I was just wondering on the M&A front, have you seen valuations come down a little bit? And just remind us, has it changed the criteria that you are looking for? Is it more geographical? Any color there on what you are looking for when you study up M&A?

Yes. I mean our criteria remain unchanged, and the targets that we seek are both software and service, although software is a focus for us. There are some geographical benefits in some locations that would be an attraction to a target if it was in the right locale to support our expansion on a global basis of our service coverage. But on the valuation side, the financial criteria of our M&A strategy remains unchanged. We are looking for accretive opportunities, and that interplays obviously with valuation quite quickly. The company has got to be performing well, and the valuation has to be appropriate, so that it is accretive to us. Have valuations come down? Boy, the discussions are a little bit easier than they were, say, a year ago. It doesn't mean that they are not tough. And I think we still see in the healthcare space and certainly biosimulation space that in addition to market valuation metrics that might be referred to in valuation discussions, we also see a lot of private companies, private equity funding that comes into play, and that affects valuations as well. So the headline is: no valuation discussions are better than they were before. That doesn't mean that they are necessarily easy parts of the discussions that are ongoing in terms of target candidates that we interact with.

Sounds good. And then just quickly, quick two questions on the financial side. There was a little jump here on the SG&A side, I guess, 57% of revenues in the fourth quarter. I think you discussed maybe the contract costs went up, or maybe the payroll went up as well and more employees added to the team. Can you just help us understand maybe SG&A going forward? What you expect there?

Yes. Fair enough. A couple of factors in play there. I will let Will go through the details of the payroll. We did a merger of our three legal entities, essentially SLP, Cognigen, and DILIsym from the acquisitions to roll up into one legal entity for multiple purposes that support both our consolidation, integration process internal for the company as well as external cost savings on a number of fronts that will now accrue to us that ultimately had some changes in our payroll systems coming together. That didn't change our payroll cost overall for the year, but lumped it into quarters a little bit non-consistent or non-linearly. The other expenses that came into play in the fourth quarter, all of which if you look and focus on EBITDA, our EBITDA percentage of revenue only declined a couple of points in an environment in which we saw revenues in the back half of the year well below where we expected to be. And in terms of our most precious asset, our employees are scientists. Not only is it a compensation competitive marketplace that we need to respond to, and that provides some pressure and uplift to the costs in that area, but as well while revenue in the service business was down, it wasn't a situation in which we were going to shave off our organization to reduce expenses to match that revenue. These are valued assets in this industry. And so there's some play there as well in terms of OpEx being a little high in the fourth quarter. Our expectations are on a go-forward basis that nothing has fundamentally changed in terms of our OpEx, our profitability profile. And we expect that fourth quarter percentage of revenue on OpEx to be a bit of an anomaly and will return to where we have been the last year or two in OpEx on a go-forward basis.

Great. That's it from me. Thank you very much and congrats on the quarter.

Take care, Frank.

There are no further questions at this time. I would like to turn the floor back over to Mr. Shawn O'Connor for closing comments.

Very good. Well, thank you everyone. We are pleased that we saw some uptick in terms of where we came in, in the fourth quarter compared to a challenging third quarter and are very pleased with the momentum on both sides of our business, both the software and service businesses as they enter our new fiscal year. Look forward to reporting further results a quarter from now to you. Take care. Thanks a lot.

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation and enjoy the rest of your day.